Velocin

Startup

Velocin develops engineered protein-based vaccines, starting with enteroviruses, where licensed vaccines exist only for polio and, regionally, for EV-A71. We make recombinant virus-like particles without culturing the pathogen, engineered so the immune response targets protective epitopes rather than decoy regions. Preclinical results include complete protection in a challenge model and 10 to 100-fold higher yields than inactivated whole-virus production. A tetravalent candidate is in preclinical evaluation. We are building a parametric vaccine design system (PVDS) that is intended to make this repeatable by ranking candidates before they are made, so the wet lab tests only what is worth testing. The same system is intended to transfer to influenza, coronaviruses and pandemic-preparedness targets, each starting faster and cheaper than the last. We are looking for development and commercial partners to bring our lead enterovirus candidate to the clinic and apply the design system to new pathogens.

website